In vitro evaluation of drug delivery behavior for inhalable amorphous nanoparticle formulations in a human lung epithelial cell model.

摘要: Respiratory tract infections caused by multidrug-resistant (MDR) Gram-negative bacteria such as Pseudomonas aeruginosa are serious burdens to public health, especially in cystic fibrosis patients. The combination of colistin, a cationic polypeptide antibiotic, and ivacaftor, transmembrane regulator (CFTR) protein modulator, displays synergistic antibacterial effect against P. aeruginosa. primary aim the present study is investigate transport, accumulation toxicity novel nanoparticle formulation containing colistin ivacaftor lung epithelial Calu-3 cells. cell viability results demonstrated that alone or with physical mixture showed significant at an concentration 10 μg/mL higher. However, cellular was significantly reduced formulation. Ivacaftor transport into cells reached plateau rapidly compared colistin. Colistin across monolayer less than ivacaftor. A substantial amount (46-83%) independent dose, accumulated following from apical basal chamber, whereas intracellular relatively low (2-15%). reducing both drugs potential protective effects bovine serum albumin (BSA), which could be promising safer option for treatment respiratory MDR